BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Conditions
- MesotheliomaNon Small Cell Lung CancerMalignant Peripheral Nerve Sheath TumorsSolid TumorPancreatic AdenocarcinomaAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 320
- Registration Number
- NCT06937970
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Rocky Mountain Cancer Centers, LLP - Oncology, Lone Tree, Colorado, United States
🇺🇸Sarah Cannon Research Institute (SCRI) - HealthONE Location, Denver, Colorado, United States
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 600
- Registration Number
- NCT06937229
- Locations
- 🇺🇸
Local Institution - 2609, Chandler, Arizona, United States
🇺🇸Local Institution - 2620, Canoga Park, California, United States
🇺🇸Local Institution - 2614, San Diego, California, United States
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-05-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 300
- Registration Number
- NCT06929273
- Locations
- 🇧🇬
Local Institution - 0113, Sliven, Bulgaria
🇺🇸Local Institution - 0120, Glendale, Arizona, United States
🇺🇸Local Institution - 0123, Torrance, California, United States
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 560
- Registration Number
- NCT06926868
- Locations
- 🇺🇸
Local Institution - 0303, Hot Springs, Arkansas, United States
🇺🇸Local Institution - 0307, Cerritos, California, United States
🇺🇸Local Institution - 0308, Cerritos, California, United States
A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: BMS-986419 Matching PlaceboDrug: Moxifloxacin Matching Placebo
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 74
- Registration Number
- NCT06846866
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 250
- Registration Number
- NCT06882785
- Locations
- 🇯🇵
Local Institution - 0033, Tottori, Japan
🇯🇵Local Institution - 0006, Wakayama, Japan
🇯🇵Local Institution - 0030, Yamagata, Japan
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
- Conditions
- Systemic Lupus Erythematosus (SLE)Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
- Interventions
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT06875960
- Locations
- 🇺🇸
Local Institution - 0001, Farmington, Connecticut, United States
🇺🇸Local Institution - 0002, New York, New York, United States
🇺🇸Local Institution - 0003, Jackson, Tennessee, United States
A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 56
- Registration Number
- NCT06877702
- Locations
- 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States
🇺🇸Local Institution - 0002, Lenexa, Kansas, United States
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
- Conditions
- Juvenile Psoriatic Arthritis
- Interventions
- Other: Placebo
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT06869551
- Locations
- 🇨🇿
Fakultni nemocnice Olomouc, Olomouc, Olomoucký Kraj, Czechia
🇺🇸Local Institution - 0038, Lancaster, California, United States
🇺🇸Local Institution - 0020, Chicago, Illinois, United States
A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 130
- Registration Number
- NCT06855771
- Locations
- 🇺🇸
Local Institution - 0088, Anchorage, Alaska, United States
🇺🇸Local Institution - 0099, Boise, Idaho, United States
🇺🇸Local Institution - 0090, Boston, Massachusetts, United States